Search clinical trials for: TAK-625

Total 6324 results

Takeda

Active, not recruiting

A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)

Alagille Syndrome (ALGS)

Japan
Takeda

Active, not recruiting

A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)

Progressive Familial Intrahepatic Cholestasis (PFIC)

Japan
Millennium Pharmaceuticals, Inc.

Completed

A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia

Idiopathic Hypersomnia

United States, Japan
Takeda

Completed

Phase 1 TAK-925 Study in Healthy Adult and Elderly Volunteers and Participants With Narcolepsy

Healthy Participants and Patients With Narcolepsy

Japan
Millennium Pharmaceuticals, Inc.

Completed

Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)

Obstructive Sleep Apnea

United States
Takeda

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Participants With Narcolepsy

Healthy Participants | Narcolepsy

Japan
GlaxoSmithKline

Completed

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B (COPD)

Pulmonary Disease, Chronic Obstructive

South Africa, United States, Canada, Ukraine, United Kingdom, Denmark, Czechia
Takeda

Completed

A Study of Danavorexton (TAK-925) in Adults With Obstructive Sleep Apnea

Sleep Apnea

Australia
GlaxoSmithKline

Completed

A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo in Subjects With COPD

Pulmonary Disease, Chronic Obstructive

Taiwan, Thailand, China, Philippines, Korea, Republic of
Takeda

Completed

A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease

Fabry Disease

China
GlaxoSmithKline

Completed

Pharmacokinetics Of Umeclidinium and Vilanterol in Healthy Chinese, a Randomized, Open Label, 3 Crossover Study.

Pulmonary Disease, Chronic Obstructive

China
Henan Cancer Hospital

Not yet recruiting

Application of Douyin in Patients With Bone and Soft Tissue Malignant Tumors During Perichemotherapy

Chemotherapy | Malignant Tumor
Henan Cancer Hospital

Not yet recruiting

Application of Douyin in Perioperative Period of Malignant Tumor Patients

Perioperative Period | Malignant Tumor of Bone
Takeda
Takeda Development Center Americas, Inc.

Recruiting

A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Thrombotic Thrombocytopenic Purpura (TTP)

United States, Spain, Italy, Greece, United Kingdom, Argentina, Poland, Austria
Kaohsiung Medical University Chung-Ho Memorial...

Completed

Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI

Colorectal Cancer

Taiwan
Takeda
Shire; Takeda Development Center Americas, Inc.

Recruiting

A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

Thrombotic Thrombocytopenic Purpura (TTP)

China, United States, France, Japan, Poland, Germany, Austria, Spain, Italy, Switzerland, United Kingdom
University of Tasmania

Enrolling by invitation

TapTalkTest Project:Development of a Non-invasive Screening Test to Detect Risk of Alzheimer's Disease Pathology (TapTalkTest)

Dementia | Alzheimer Disease | Speech Disorders | Movement Abnormalities

Australia
Grifols Therapeutics LLC

Completed

Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis (PRIVIG)

Multiple Sclerosis, Relapsing-Remitting

Canada, Israel, United States, Austria, Czech Republic, Germany, Greece, Hungary, Poland, Slovakia, Sweden, United Kingdom
GlaxoSmithKline

Completed

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, Russian Federation, United States, Bulgaria, Estonia, United Kingdom
Takeda

Recruiting

A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery

Sleep Apnea

United States
Takeda
Takeda Development Center Americas, Inc.

Recruiting

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Children and Teenage Transplant Recipients With CMV Infection

Cytomegalovirus (CMV)

France, United Kingdom, Israel, Germany, Spain, Belgium, China, Brazil, United States, Japan
Oregon Research Institute

Recruiting

A Study of Dual-task Exercise Training to Prevent Falls Among Older Adults With Mild Cognitive Impairment

Aging | Mild Cognitive Impairment | Accidental Falls

United States
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Recruiting

A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

Thrombotic Thrombocytopenic Purpura (TTP)

United States, Spain, Poland, Italy, Germany, France, Switzerland, Austria, Japan, United Kingdom
Takeda
Takeda Development Center Americas, Inc.

Completed

Maribavir Food-Effect Study in Healthy Adults Participants

Healthy Volunteers

United States
US Department of Veterans Affairs

Completed

Fitness and Daily Function in Adults

Cardiovascular Disease

United States
Afyonkarahisar Health Sciences University

Recruiting

Dual Task Gait Performance in Pediatric Oncology Patients

Pediatric Cancer

Turkey
St. Luke's-Roosevelt Hospital Center

Completed

Transplant and Addiction Project (TAP) - 1

Substance-Related Disorders | End Stage Liver Disease | End Stage Renal Disease

United States
Takeda

Completed

A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection

Cytomegalovirus (CMV)

Japan
Takeda

Completed

Efficacy and Safety of Ramelteon on Chronic Insomnia

Chronic Insomnia
Takeda

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-925 Study in Sleep-Deprived Healthy Adults

Healthy Volunteers

United States
University of Iceland
Uppsala University

Recruiting

The Lóa Study: A Brief Digital Intervention for Women With Intrusive Memories in the SAGA Cohort

Intrusive Memories of Traumatic Event(s)

Iceland
Takeda

Completed

Single-Dose Phase 1 Study of TAK-792

Healthy Male Adults Participants

Japan
Takeda

Withdrawn

A Phase 1, Single and Multiple Dose Study of TAK-137

Healthy Japanese Adult Male

Japan
Kaohsiung Medical University Chung-Ho Memorial...

Unknown

Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Taiwan
Neurocrine Biosciences
Takeda

Terminated

A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants

Schizophrenia, Cerebellar Ataxia

United Kingdom
Takeda

Completed

A Study of TAK-951 in Healthy Adults

Healthy Volunteers

United States
Takeda

Completed

A Study of TAK-951 in Healthy Adults

Healthy Volunteer

United States
Takeda

Terminated

Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.

Attention-Deficit/Hyperactivity Disorder

United States
Takeda

Terminated

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Cardiovascular Disease | Type 2 Diabetes

United States, France, Poland, Ukraine, Germany, Hong Kong, Taiwan, Argentina, Israel, Mexico, Bulgaria, Malaysia, Romania, Canada, Korea, Republic of, New Zealand, Peru, Estonia, Philippines, Russian Federation, Czech Republic, H... and more
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus | Lupus Erythematosus, Systemic

United States
Takeda
Takeda Development Center Americas, Inc.

Completed

A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery

Postoperative Gastrointestinal Dysfunction

United States, Germany
Neurocrine Biosciences
Takeda

Completed

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

Schizophrenia | Healthy Volunteers

United States
Neurocrine Biosciences
Takeda

Completed

TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants

Depressive Disorder

United Kingdom
Millennium Pharmaceuticals, Inc.

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult Participants

Healthy Volunteers

United States
Takeda

Completed

Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants

Schizophrenia

United States
Takeda

Terminated

Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes (GRAND-307)

Type 2 Diabetes Mellitus

Taiwan, China, Korea, Republic of, New Zealand, Australia
Takeda

Completed

TAK-438 - Safety, Blood Levels & Effects of Repeated Doses (TAK-438_107)

Gastroesophageal Reflux Disease (GERD) | Erosive Esophagitis(EE)

United Kingdom
Takeda

Withdrawn

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-988 in Healthy Participants

Healthy Volunteers

United States
Neurocrine Biosciences
Takeda

Completed

Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia

Friedreich Ataxia

United States
Takeda

Completed

Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Participants

Japanese Healthy Adult Male Participants

Japan

3

Subscribe